Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

RIFATER

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

Standard Dose
50MG;300MG;120MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview RIFATER is listed in Drugs@FDA under application 050705 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ISONIAZID; PYRAZINAMIDE; RIFAMPIN Form and strength TABLET;ORAL - 50MG;300MG;120MG Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2025-12-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview RIFATER is listed in Drugs@FDA under application 050705 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ISONIAZID; PYRAZINAMIDE; RIFAMPIN Form and strength TABLET;ORAL - 50MG;300MG;120MG Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2025-12-05 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
RIFATER (ISONIAZID; PYRAZINAMIDE; RIFAMPIN) | Drug Monograph | MedicHelpline